Stengone Carmine N.'s Form 4 filing
Contineum Therapeutics, Inc. (CTNM) · filed Sep 8, 2026
- Accession no.
- 0001628280-26-060962
- Filed
- Sep 8, 2026, 6:08 PM ET
- Trade date
- Sep 8, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $41.1K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Stengone Carmine N.CIK 0001861519 | Director, Officer (CEO and President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Class A Common Stock | MOption exerciseAcquired | +2,500 | $1.01 | +$2,525 | 19,717 | Direct | |
| Sep 8, 2026 | Class A Common Stock | SSaleDisposed | −2,500 | $16.46 | −$41,141.5 | 17,217 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Class A Common Stock | MOption exerciseDisposed | −2,500 | $0.00 | $0 | 274,430 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.